
usd feb pm et
summari develop manufactur market medic devic intervent medic
specialti three segment cardiovascular rhythm manag medsurg
price-to-earnings oper ep
risk assess reflect compani stabl
oper within competit area health care
industri high growth prospect howev
moder level debt net debt total capit
june continu success also
depend abil continu innov
commerci new innov -- easi task
fiscal year end dec ep estim base cfra
oper earn histor earn report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
jan pm stock trade
target price recent
chang highlight
section stock report updat
invest rationale/risk section
stock report updat shortli
latest news stori marketscop
rais price
ep
estim report ep
vs expect
due tax benefit start
ep estim januari
pre-announc organ sale growth
guidanc primarili due
soft cardiac rhythm manag
neg sale impact million due
novel coronaviru potenti impact
procedur volum china addit
growth guidanc vs full-year
guidanc find
conserv look ahead
high expect structur heart
edg soon-to-be-launch acur
exalt single-us duodenoscop
watchman flx launch
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview develop market minim invas medic devic
use broad rang intervent medic specialti offer product sale
seven core categori intervent cardiolog sale cardiac rhythm manag
endoscopi peripher intervent urolog pelvic health neuromodul
electrophysiolog seven core categori group three report segment
cardiovascular rhythm manag medsurg
cardiovascular segment includ intervent cardiolog peripher intervent
intervent cardiolog busi develop manufactur technolog diagnos treat
coronari arteri diseas cardiovascular disord includ structur heart condit product
includ drug-elut coronari stent system broad line product offer treat atherosclerosi
princip caus coronari arteri obstruct diseas devic structur heart therapi
watchman appendag closur acur aortic valv system brand peripher intervent
busi develop manufactur product diagnos treat peripher arteri diseas includ
broad line medic devic use percutan translumin angioplasti pta peripher
vascular diseas well product diagnos treat eas variou form cancer product
offer includ product stent balloon cathet wire atherectomi peripher
rhythm manag segment includ cardiac rhythm manag electrophysiolog
busi develop manufactur varieti implant devic monitor heart
deliv electr treat cardiac abnorm implant cardiovert defibril
pacemak current gener defibril reson famili devic avail
major market around world electrophysiolog busi develop manufactur
less-invas medic technolog use diagnosi treatment rate rhythm disord
heart includ broad portfolio therapeut diagnost cathet varieti equip
use electrophysiolog lab
medsurg segment includ endoscopi urolog pelvic health neuromodul
endoscopi busi develop manufactur devic diagnos treat broad rang
gastrointestin gi pulmonari condit innov less invas technolog urolog
pelvic health busi develop manufactur devic treat variou urolog pelvic condit
male femal anatomi includ kidney stone benign prostat hyperplasia bph erectil
dysfunct male incontin pelvic floor disord abnorm uterin bleed uterin fibroid
polyp neuromodul busi develop manufactur devic treat variou neurolog
movement disord manag chronic pain
competit landscap face signific competit across product line market
primari competitor includ plc cook medic well wide rang
medic devic compani sell singl limit number competit product particip
specif market segment like mani medic devic compani also face competit
non-med devic compani pharmaceut compani may offer altern therapi
diseas state could also treat use product
financi trend revenu grew billion compani five-year compound
annual growth rate compound-annual-growth-rate revenu meanwhil five-year compound-annual-growth-rate adjust ep
adjust ep vs spend larg amount research
develop year end decemb spent billion
revenu septemb elev net debt total capit ratio
leverag ratio net debt trailing-twelve-month ebitda
execut vice-president
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
slightli overvalu usd
neutral sinc januari technic indic
neutral
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
next month neutral expect
compani continu achiev robust organ
growth mid- high-single-digit revenu
growth driven new product
data provid estim world-wide medic
devic sale grow
time think potenti slowdown
macroeconom growth could pressur
industri driver yet sub-industri
includ mani product area
histor recession-resist
equip use non-elect procedur
gener see posit long-term
fundament medic devic manufactur
includ increas global demand
popul rise outlay
result steadi flow innov product
revenu growth
polit regulatori perspect
medic devic industri larg avoid
scrutini unlik area health
drug maker fact medic devic tax
final repeal decemb remov
signific risk sale devic maker
think industri continu
dwindl industri come back
favor especi sinc valuat health
rel
forward price-to-earn basi think
higher valuat sub-industri
mostli warrant margin expans
revenu growth opportun associ
 medic devic regul
mdr go effect may
follow vitro devic
regul ivdr goe effect
devic compani made much
commentari around introduct mdr
reason believ new
regul could neg impact
industri exampl juli
submit letter world trade
organ request mdr ivdr
delay three year also novemb
associ critic slow piecem
implement new regulatori
accord evalu
billion valu prior
five-year averag deal total
billion industri debt level measur
net debt rel total capit appear
declin substanti follow
sever year increas think
industri could see increas deal
especi new ceo sever
major firm
expect industri earn rise
low-double-digit percentag driven sale
new product command higher
margin project industri oper
ebit margin
estim margin
 health equip
valu composit index
 health equip
sub-index rose vs declin
base index
five-year market price perform feb
note sector sub-industri inform base
past perform indic futur perform
reli upon
becton dickinson compani
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
pm et cfra keep strong buy opinion share boston scientif
lower price target base
ep estim fda warn physician last friday
march potenti increas long-term mortal use
paclitaxel-co balloon paclitaxel-elut stent treat peripher arteri
diseas forecast warn like neg impact sale
eluvia drug-elut stent coat paclitaxel lower ep
estim ep maintain
strong buy opinion share compani still wide
promis pipelin product /kevin huang cfa
pm et cfra reiter strong buy opinion share boston
scientif corpor lift target
ep estim multipl exce
bsx five-year rang see strong potenti
compani promis product portfolio posit expand
geograph therapeut market ep vs exceed
estim initi ep sale increas
organ billion organ medsurg segment grew
rhythm neuro cardiovascular emerg market sale
area strength sale rose organ
expect lower volum tuck-in acquisit manag
focus effort integr see mani catalyst
releas wavewrit spinal cord stimul data
combo studi continu watchman growth geograph
increas util well launch lotu edg /kevin
analyst research note compani news
pm et cfra maintain buy opinion share boston scientif
rais price
ep estim report ep vs
expect due tax benefit start ep estim
januari pre-announc organ sale growth
guidanc primarili due soft cardiac rhythm manag
busi anticip neg sale impact
million due novel coronaviru potenti impact procedur
volum china addit suppli chain disrupt result
provid weaker-than-expect organ growth guidanc vs
full-year guidanc find conserv look
ahead high expect structur heart busi
includ recent launch lotu edg soon-to-be-launch acur
exalt single-us duodenoscop watchman flx launch
 /kevin huang cfa
et cfra reiter buy opinion share boston scientif
corpor rais price target
base multipl ep estim believ
warrant premium multipl rel histor level
compani grow return capit ep vs met
expect organ sale growth acceler
larg due new product launch organ basi sale grew
cardiovascular segment follow growth medsurg
rhythm neuro mani analyst call rais concern
upcom data ischemia trial schedul present
novemb primari concern data unlik show
signific benefit intervent cardiolog approach vs optim
medic therapi alon patient stabl ischem heart diseas
believ neg outcom even worst-cas scenario highli
pm et cfra lower opinion share boston scientif buy
strong buy lift target base
multipl ep estim multipl
exce rang see strong potenti compani
product portfolio ep vs equal estim
rais ep lower ep
sale increas yoy organ billion
adjust oper margin increas basi point yoy
organ basi medsurg segment grew rhythm neuro
cardiovascular emerg market continu area strength
sale grew organ follow growth prior-year period
spite concern rais fda earli year relat use
drug pacliataxel drug-elut stent de think eluvia de
continu growth driver expect fda provid
updat guidanc paclitaxel soon /kevin huang cfa
pm et cfra maintain strong buy opinion share boston
scientif maintain target
ep estim multipl exce rang
see strong potenti compani promis product portfolio
ep vs equal estim lift ep
sale increas organ billion
organ medsurg segment grew rhythm neuro
cardiovascular sale growth weaker expect
sever event includ fda concern relat paclitaxel
chemotherapi treatment fda halt sale transvagin mesh product
state-mand shutdown third-parti steril illinoi
despit minor setback maintain ep expect
forecast strong organ growth like
driven recent upcom key product launch lotu edg tavr
system approv fda yesterday /kevin huang cfa
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd repres
total revenu estim fiscal year
analyst estim earn per share grow
usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
